Analyst Ritu Baral from TD Cowen maintained a Buy rating on Palvella Therapeutics and increased the price target to $65.00 from $44.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors that highlight Palvella Therapeutics’ promising financial and clinical outlook. The company has a strong cash position of $70.4 million as of the second quarter of 2025, which is expected to sustain operations through the second half of 2027. This financial stability is crucial as it supports the advancement of key clinical trials, including the Phase 3 SELVA MLM trial and the Phase 2 TOIVA CVM trial, as well as the submission of a New Drug Application (NDA) and pre-launch activities.
Furthermore, the decision to raise the price target from $44 to $65 reflects confidence in the company’s execution on its lead programs and the anticipated data releases from these trials. The completion of recruitment for the SELVA trial and the adherence to timelines for data readouts are positive indicators of the company’s operational efficiency. These elements together suggest a favorable risk-reward profile for investors, justifying the Buy rating.
In another report released today, JonesTrading also maintained a Buy rating on the stock with a $56.00 price target.